PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

NCT06206096 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
RAS Mutation
Colorectal Neoplasms
Microsatellite Stable Colorectal Carcinoma

Interventions

DRUG: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody

Sponsor

Chinese PLA General Hospital